Barclays PLC Immuneering Corp Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Immuneering Corp stock. As of the latest transaction made, Barclays PLC holds 9,924 shares of IMRX stock, worth $15,084. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,924

Previous 9,924 -0.0%

Holding current value

$15,084

Previous $25,000 12.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$1.03 - $3.21 $258 - $805	-251 Reduced 2.47%	9,924 $25,000
Q2 2024 Aug 14, 2024	SELL	$1.28 - $2.75 $19,991 - $42,949	-15,618 Reduced 60.55%	10,175 $13,000
Q1 2024 May 15, 2024	SELL	$1.91 - $7.32 $17,438 - $66,831	-9,130 Reduced 26.14%	25,793 $75,000
Q4 2023 Feb 15, 2024	BUY	$4.84 - $8.44 $129,440 - $225,719	26,744 Added 326.98%	34,923 $257,000
Q3 2023 Nov 07, 2023	BUY	$7.21 - $10.68 $252 - $373	35 Added 0.43%	8,179 $63,000
Q2 2023 Aug 03, 2023	BUY	$6.49 - $13.36 $18,996 - $39,104	2,927 Added 56.11%	8,144 $82,000
Q1 2023 May 04, 2023	SELL	$3.78 - $10.38 $5,824 - $15,995	-1,541 Reduced 22.8%	5,217 $51,000
Q4 2022 Feb 13, 2023	BUY	$4.09 - $15.0 $8,867 - $32,520	2,168 Added 47.23%	6,758 $33,000
Q3 2022 Nov 03, 2022	BUY	$5.0 - $14.32 $2,150 - $6,157	430 Added 10.34%	4,590 $65,000
Q2 2022 Aug 12, 2022	SELL	$3.89 - $7.81 $11,934 - $23,961	-3,068 Reduced 42.45%	4,160 $22,000
Q1 2022 May 16, 2022	BUY	$6.47 - $16.99 $46,765 - $122,803	7,228 New	7,228 $47,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

4.59M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $40.1M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account